| scholarly article | Q13442814 |
| P2093 | author name string | David R Andes | |
| William A Craig | |||
| Dong-Gun Lee | |||
| Yoichi Murakami | |||
| P2860 | cites work | Invasive methicillin-resistant Staphylococcus aureus infections in the United States | Q29616087 |
| Risk factors for mortality of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection: with investigation of the potential role of community-associated MRSA strains | Q33392055 | ||
| Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study | Q33982863 | ||
| Resurgence of the multiresistant pneumococcus in the United States: a commentary | Q80387036 | ||
| Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets | Q83770914 | ||
| Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula | Q34139332 | ||
| In vivo pharmacodynamics of a new oxazolidinone (linezolid) | Q34142754 | ||
| Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary | Q34158152 | ||
| Vancomycin: a history | Q34472263 | ||
| Animal model pharmacokinetics and pharmacodynamics: a critical review | Q34615868 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| In vivo pharmacodynamic activity of daptomycin | Q35005549 | ||
| Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid | Q35623055 | ||
| Optimal dosage of beta-lactam antibiotics: time above the MIC and inoculum effect | Q35665090 | ||
| Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization | Q35689318 | ||
| Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients | Q35808723 | ||
| The pharmacokinetic and pharmacodynamic properties of vancomycin | Q36328971 | ||
| The role of vancomycin in the treatment paradigm | Q36328981 | ||
| Glycopeptide resistance in staphylococci | Q36621293 | ||
| In vitro susceptibility testing versus in vivo effectiveness | Q36658415 | ||
| Antimicrobial therapy of multidrug-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus | Q36658437 | ||
| Limitations of vancomycin in the management of resistant staphylococcal infections | Q36916076 | ||
| In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models | Q36932924 | ||
| Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. | Q37392917 | ||
| Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists | Q37537565 | ||
| Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model | Q37625071 | ||
| Inoculum effect | Q38663738 | ||
| Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides | Q39465279 | ||
| Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin. | Q39544770 | ||
| Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics | Q39557468 | ||
| Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin | Q39695226 | ||
| Staphylococcus aureus small colony variants are induced by the endothelial cell intracellular milieu | Q41224403 | ||
| Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 | ||
| Risk factors and treatment outcomes in osteomyelitis | Q43727524 | ||
| Staphylococci, in vitro and in vivo | Q44297163 | ||
| Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme | Q44692777 | ||
| Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections | Q45127594 | ||
| Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems | Q46487875 | ||
| Rapid decrease of free vancomycin in dense staphylococcal cultures | Q46723031 | ||
| Adverse effect of staphylococci slime on in vitro activity of glycopeptides. | Q46868222 | ||
| Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes | Q46983556 | ||
| The inoculum effect: fact or artifact? | Q53877734 | ||
| Health Care–Associated Pneumonia Requiring Hospital Admission | Q60647953 | ||
| Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect | Q70735649 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| Streptococcus pneumoniae | Q221179 | ||
| linezolid | Q411377 | ||
| vancomycin | Q424027 | ||
| P304 | page(s) | 1434-1441 | |
| P577 | publication date | 2013-01-07 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice | |
| P478 | volume | 57 |
| Q92134281 | Adjunctive ceftaroline in combination with daptomycin or vancomycin for complicated methicillin-resistant Staphylococcus aureus bacteremia after monotherapy failure |
| Q40670947 | Antibacterial activity of the novel semisynthetic lantibiotic NVB333 in vitro and in experimental infection models |
| Q34433342 | Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia |
| Q37538738 | Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models |
| Q33724436 | Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model. |
| Q34596470 | Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of Ceftaroline Fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter |
| Q92127147 | Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans |
| Q42111799 | Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model |
| Q36571798 | In Vivo Pharmacodynamics of Cefquinome in a Neutropenic Mouse Thigh Model of Streptococcus suis Serotype 2 at Varied Initial Inoculum Sizes |
| Q54203694 | In vivo and in vitro effects of a ClpP activating antibiotic against vancomycin resistant enterococci. |
| Q64072703 | In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model |
| Q35105932 | In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model |
| Q53070940 | Individualising Therapy to Minimize Bacterial Multidrug Resistance. |
| Q34381321 | Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens |
| Q90701768 | Pharmacodynamics of ClpP-Activating Antibiotic Combinations against Gram-Positive Pathogens |
| Q41992893 | Pharmacodynamics of teicoplanin against MRSA. |
| Q40414549 | Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection. |
| Q36644897 | Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure. |
| Q41648730 | Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin |
Search more.